Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) reported its financial results for the quarter ended March 31, 2014. These results are discussed in Galmed’s Form 6-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 14, 2014, which includes Galmed’s unaudited condensed consolidated financial statements for the three months, ended March 31, 2014, together with related and certain other information. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) weekly performance is -7.99%. On last trading day company shares ended up $6.45. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) distance from 50-day simple moving average (SMA50) is -35.66%.
Delcath Systems, Inc. (NASDAQ:DCTH reported financial results and corporate developments for the fiscal first quarter ended March 31, 2014.First quarter 2014 cash utilization of $4.5 million, lower than guidance of $5 to $6 million. Delcath Systems, Inc. (NASDAQ:DCTH) shares fell -3.20% in last trading session and ended the day on $2.72. DCTH Gross Margin is 37.50% and its return on assets is -108.90%. Delcath Systems, Inc. (NASDAQ:DCTH) quarterly performance is -46.87%.
7 MAY 2014 SIGA Technologies, Inc (NASDAQ:SIGA) is a pharmaceutical company specializing in the development and commercialization of pharmaceutical solutions for some of the lethal disease-causing pathogens in the world. Analysts expect that SIGA Technologies will post $1.03 EPS for the current fiscal year.SIGA Technologies, Inc. (NASDAQ:SIGA) shares moved up 0.75% in last trading session and was closed at $2.68, while trading in range of $2.63 – $2.73. SIGA Technologies, Inc. (NASDAQ:SIGA) year to date (YTD) performance is -18.04%.
8 MAY 2014 Derma Sciences Inc (NASDAQ:DSCI), reported financial and operating results for the three months ended March 31, 2014.Total net sales increased 5.3% to $19.8 million. Traditional Wound Care (TWC) product sales increased 1.2% to $11.4 million. Derma Sciences Inc (NASDAQ:DSCI) ended the last trading day at $8.88. Company weekly volatility is calculated as 5.82% and price to cash ratio as 10.16. Derma Sciences Inc (NASDAQ:DSCI) showed a negative weekly performance of -7.21%.
IMRIS Inc (NASDAQ:IMRS) reported that a substantial majority of the shareholders approved the management proposals: Director nominees H. David Graves, Stephen Armstrong, Carey Diamond, William Fraser, James Hickey, Blaine Hobson, and Jay D. Miller were each re-elected to IMRIS’ Board of Directors. Each director received at least 98.62 percent of the vote cast “For.” IMRIS Inc (NASDAQ:IMRS) weekly performance is -6.09%. On last trading day company shares ended up $1.08. Analysts mean target price for the company is $2.80. IMRIS Inc (NASDAQ:IMRS) distance from 50-day simple moving average (SMA50) is -26.90%.
Leave a Reply